Related Experiment Video

Updated: May 19, 2026

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
07:25

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

Treatment of chronic delta hepatitis

Cihan Yurdaydin1

  • 1University of Ankara Medical School, Cebeci Tip Fakultesi Hastanesi, Dikimevi, Ankara, Turkey. cihan.yurdaydin@medicine.ankara.edu.tr

Seminars in Liver Disease
|August 31, 2012
PubMed

Insights

Current treatments for chronic delta hepatitis (CDH) are limited, with interferons offering suboptimal responses. Research is ongoing for new therapies to improve outcomes for this progressive liver disease.

Area of Science:

  • Hepatology
  • Virology
  • Pharmacology

Background:

  • Chronic delta hepatitis (CDH) is the most aggressive form of viral hepatitis.
  • Effective treatment options for CDH are limited, with interferons being the only evidence-based therapy.
  • Current interferon treatments yield suboptimal sustained response rates (25-30%).

Purpose of the Study:

  • To review the current treatment landscape for chronic delta hepatitis.
  • To identify limitations and unanswered questions regarding interferon therapy.
  • To explore emerging therapeutic strategies for CDH.

Main Methods:

  • Review of existing literature on CDH treatment.
  • Analysis of interferon efficacy and limitations.
  • Discussion of nucleos(t)ide analogs and novel therapeutic targets.

Main Results:

  • Interferons, including pegylated interferon (Peg-INF), remain the cornerstone of CDH treatment but offer limited efficacy.
  • Nucleos(t)ide analogs have shown ineffectiveness in CDH treatment.
  • Key challenges include standardizing viral load quantification and identifying predictive treatment markers.

Conclusions:

  • There is a critical need for more effective treatments for chronic delta hepatitis.
  • Further research is required to optimize interferon therapy and develop novel agents.
  • Emerging therapies like entry inhibitors and prenylation inhibitors show future promise for CDH management.

More Related Videos

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks10:28

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks

Published on: June 26, 2020

Related Concept Videos

Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Chronic Pancreatitis II: Collaborative Care01:29

Chronic Pancreatitis II: Collaborative Care

The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Cirrhosis I: Introduction01:23

Cirrhosis I: Introduction

Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...
Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...